Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tempest Therapeutics, Inc. - Common Stock (NQ:TPST)

1.770 -0.090 (-4.84%)
Streaming Delayed Price Updated: 3:09 PM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tempest Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
The company is preparing for the Phase 3 study start in the first quarter of 2025 
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Extends Limited Duration Stockholder Rights Plan
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal study 
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
Expansion of leadership team to strengthen global clinical expertise 
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday? ↗
Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin... 
Via Benzinga
News headline image
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
News headline image
TPST Stock Earnings: Tempest Therapeutics Misses EPS for Q2 2024 ↗
TPST stock results show that Tempest Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
News headline image
$55M Bet On Archer Aviation? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying ↗
 
Via Benzinga
News headline image
Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Gold Rises 1%; Accenture Shares Surge After Q3 Results ↗
 
Via Benzinga
News headline image
What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday? ↗
Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows a six-month survival improvement in hepatocellular carcinoma patients... 
Via Benzinga
News headline image
Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today? ↗
NLS Pharmaceutics stock is down on Thursday as shares of NLSP come off of a recent rally that was fueled by heavy trading on Tuesday. 
Via InvestorPlace
News headline image
Why Is Avrobio (AVRO) Stock Moving Today? ↗
Avrobio stock is in the news Thursday as the company prepares for a merger and reverse stock split of AVRO after markets close today. 
Via InvestorPlace
News headline image
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Is Tempest Therapeutics (TPST) Stock Up 45% Today? ↗
Tempest Therapeutics stock is up on Thursday with heavy trading of TPST shares ahead of a presentation taking place this morning. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Pre-market stock movers are a hot topic on Thursday and we have all the hottest news behind these movements this morning! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
Webcasted conference call on Thursday, June 20, 2024 at 8:30 a.m. ET 
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Tempest to Participate in Upcoming Investor Conferences
From Tempest Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.